BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the enrollment of the first patients in a third Phase 3 clinical trial for DEXTENZATM (sustained release dexamethasone) 0.4mg Intracanalicular Depot, for the treatment of post-surgical ocular inflammation and pain. Based on the results of the Company’s two previously c
Combined phacoemulsification-viscogonioplasty and phacoemulsification alone may have the same effects on long-term IOP in primary angle-closure glaucoma, according to a study.The prospective randomized clinical trial evaluated 46 eyes that underwent ph…
(MedPage Today) — Little to no impact on most services, researchers at Anthem find
ARLINGTON, Va.–(BUSINESS WIRE)–The CEA Foundation is pleased to announce the winners of its first “technology that improves lives” video contest. Aipoly, HelpAround, Los Angeles Low Vision, Perceptive Devices and WHILL were selected from more than 20…
Miguel Hernández University in Alicante, Spain, launched this month the first worldwide online university course in refractive surgery, a comprehensive, 250-hour, 1-year, distance learning program leading to a university certificate.“Something unique. A very innovative approach to a subspecialty area that is neglected by traditional residency curricula. An opportunity for young and less young ophthalmologists around the world to have access to a course of the highest academic standard without having to move or commute,” Jorge L. Alió, MD, PhD, course director, told Ocular Surgery News.
(MedPage Today) — Advisory panel searches for ways to keep rural hospitals solvent